Adeno-associated virus (AAV)-mediated gene therapy has emerged as a promising treatment for hemophilia B.
Data on safety and durability from 13 years of follow-up in a cohort of patients who had been successfully treated with scAAV2/8-LP1-hFIXco gene therapy are now available.
